Home » FDA DENIES APPROVAL OF INSPIRE'S DRY EYE DRUG
FDA DENIES APPROVAL OF INSPIRE'S DRY EYE DRUG
Inspire Pharmaceuticals has announced that the FDA has sent the company a second
letter outlining steps needed before the agency can approve its dry eye drug,
diquafosol tetrasodium. Diquafosol tetrasodium is a P2Y2 receptor agonist, targeted
to treat dry eye disease through rehydration of the ocular surface.
Dry eye is a hard-to-treat condition in which a person's eyes produce too few
tears, or tears of too poor quality, to lubricate the eye and keep it comfortable.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May